Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Oncotarget | The role of pyrethroid derivatives in autophagy and apoptosis crosstalk signaling and potential risk for malignancies

News

December 28, 2022
PRESS RELEASE: On December 17, 2022, a new research paper was published in Oncotarget, entitled, “The role of pyrethroid derivatives in autophagy and apoptosis crosstalk signaling and potential risk for malignancies.” continue reading »

Oncotarget | Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients

Oncotarget

December 22, 2022
PRESS RELEASE: A new research paper was published in Oncotarget, entitled, “Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.” continue reading »

A New Method of Targeting Exosomes in Precision Medicine

Oncotarget

December 20, 2022
Oncotarget published a new editorial perspective by Dr. Mujib Ullah, entitled, "The future of bioorthogonal-chemistry for targeting of exosomes in precision medicine." continue reading »

Behind the Study: APOE Genotype Determines Cancer Patients Most Likely to Benefit From Exercise

Oncotarget

December 13, 2022
Dr. Kerri Winters-Stone and Dr. Jacob Raber describe a research paper they co-authored that was published by Oncotarget, entitled, “Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention.” continue reading »

Oncotarget | Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma

News

December 13, 2022
PRESS RELEASE: A new research paper was published in Oncotarget's Volume 13 on August 16, 2022, entitled, “Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.” continue reading »